The new generic drug has been approved for treatment of bovine respiratory disease and associated pyrexia in beef and ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...
New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...
The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...
Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results